BBK Worldwide, a clinical trial marketing firm announced it is making the availability of its mobile apps My Clinical Study Buddy®for patients and My Protocol Pal® for investigators free of charge throughout 2015.
BBK Makes Mobile App Suite Available Free of Charge
BBK Worldwide, a clinical trial marketing firm announced it is making the availability of its mobile apps My Clinical Study Buddy® for patients and My Protocol PalSM for investigators free of charge throughout 2015. BBK’s mobile apps are built on its cloud-based content management engine, TrialCentralNetSM (TCN®), to help companies reduce enrollment timelines and provide insight into key patient recruitment pressure points. What’s more, BBK’s engagement solutions, RSG® Card and RSG® Arrive are also available through TCN for a seamless connection to My Clinical Study Buddy®. These offerings allow the study community to more easily reimburse and arrange travel for relevant studies, a major and often overlooked bottleneck for sites and sponsors – especially with the complex travel and reimbursements inherent in rare disease trials.
Read the full release here.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.